ClinicalTrials.gg
CompletedNCT01436955Updated Mar 3, 2015

A Study of RG1662 in Individuals With Down Syndrome

A Phase 1 interventional study of Placebo and RG1662 in Down Syndrome, sponsored by Hoffmann-La Roche. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2015-03-03.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Down Syndrome by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Down Syndrome · Hoffmann-La Roche.

Started
2011
the only one that year
Phase 1
2 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Down Syndrome by Hoffmann-La Roche, this one is the only one that started in 2011, is one of 2 in phase 1, and was the 2nd registered.

Down Syndrome

439 studies on the registry are indexed under Down Syndrome; 100 are open to participants now.

Browse Down Syndrome studies →

Open to participants now

None of the 10 studies in Down Syndrome by Hoffmann-La Roche is open now. The open studies under Down Syndrome, anywhere →

Who these studies take

Of the 75 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 58 (77%) stop at 75 or younger; 61 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Down Syndrome by Hoffmann-La Roche as a file.
02

Study summary

This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is 38 days.

03

Conditions studied

  • Down Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult individuals, 18 to 30 years of age, with diagnosis of Down Syndrome (confirmed by karyotype)
  • Males and non-pregnant non-lactating females
  • Parent or legal guardian/representative and caregiver willing to give written
  • Subject willing and assenting or consenting to participate

Exclusion criteria

Exclusion Criteria:

  • Major depressive disorder not adequately controlled by a selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor
  • Subjects meeting clinical diagnostic criteria for autistic spectrum disorder, attention deficit or hyperactivity disorder unlikely to cooperate and take part successfully in the study assessments
  • Subjects with other primary psychiatric diagnosis
  • Subjects with evidence or meeting clinical diagnosis of dementia
  • Subjects with personal history of cardiac abnormalities; patients that have previously undergone congenital heart surgery can be enrolled provided they have no residual complication requiring intervention (e.g. pace maker)
  • Subjects with obstructive pulmonary disease or asthma that is not adequately treated (oral are not allowed)
  • Subjects with thyroid dysfunction that is not adequately controlled and stabilized on treatment for at least 8 weeks
  • Subjects with sustained elevated supine blood pressure (SBP/DBP) at rest exceeding 140/90 mmHg or notable resting tachycardia (mean HR > 60 bpm) or blood pressure below 90/40 mmHg
  • Subjects who have taken any other medications within 3 months
  • (BMI) > 40 kg/m2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    A

    Drug: RG1662

  • Placebo comparator
    B

    Drug: Placebo

Interventions

  • DrugPlacebo

    multiple oral doses

  • DrugRG1662

    Cohorts receiving multiple oral doses

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of adverse events

    Time frame: 16 weeks

Secondary outcomes

  1. Neurocognitive assessment: CANTAB (Computerized battery for assessing motor practice, reaction time and memory)/standard cognitive tests

    Time frame: 5-6 weeks

  2. Pharmacokinetics: Serum concentration/area under the concentration-time curve (AUC)

    Time frame: 5-6 weeks

07

Study locations

9 sites
  • Phoenix, Arizona 85013, United States
  • Little Rock, Arkansas 72204, United States
  • La Jolla, California 92037, United States
  • Aurora, Colorado 80045, United States
  • Decatur, Georgia 30033, United States
  • Chicago, Illinois 60612, United States
  • Baltimore, Maryland 21287, United States
  • Durham, North Carolina 27710, United States
  • London, NW10 7EW, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Sep 20, 2011
Start
Nov 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Last update
Mar 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01436955
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 20, 2011
Start date
Nov 2011
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Mar 3, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion